Related Experiment Video
Updated: Jan 1, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model
Michelle Van Name1, Georgeanna Klingensmith2, Bryce Nelson3
1Department of Pediatrics, Yale University, New Haven, Connecticut.
The Pediatric Diabetes Consortium (PDC) model enhances clinical trial efficiency for youth type 2 diabetes drugs. This collaborative approach streamlines protocols and oversight, aiding successful drug development.
Area of Science:
- Pediatric Endocrinology
- Clinical Trial Management
- Diabetes Research
Background:
- Completing Phase 3 clinical trials for pediatric type 2 diabetes is complex.
- The Pediatric Diabetes Consortium (PDC) was established to address these challenges.
Purpose of the Study:
- To describe the PDC Consortium model designed to improve the efficiency of pediatric diabetes clinical trials.
- To highlight the model's role in facilitating the completion of critical drug trials.
Main Methods:
- Development of a Coordinating Center and Executive Committee to centralize oversight.
- Implementation of a Consulting Group for protocol design optimization.
- Establishment of Master Service Agreements and standard Site Budgets.
- Regular conference calls for sponsor/CRO interaction and performance monitoring.
Main Results:
- The PDC model was instrumental in completing the pivotal liraglutide trial for youth type 2 diabetes.
- PDC centers exceeded enrollment targets in two ongoing diabetes studies.
- The model has successfully launched new type 2 diabetes studies.
Conclusions:
- The PDC Consortium model demonstrates effectiveness in improving pediatric clinical trial efficiency.
- Ongoing efforts aim to expand the model's application to type 1 diabetes and other related studies.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Pharmacokinetics in Pediatric Patients: Drug Metabolism

